The estimated Net Worth of Laura Sepp Lorenzino is at least $3.06 Million dollars as of 8 January 2024. Laura Lorenzino owns over 2,275 units of Intellia Therapeutics Inc stock worth over $889,082 and over the last 5 years he sold NTLA stock worth over $411,625. In addition, he makes $1,762,490 as Executive Vice President and Chief Scientific Officer at Intellia Therapeutics Inc.
Laura has made over 8 trades of the Intellia Therapeutics Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he sold 2,275 units of NTLA stock worth $65,679 on 8 January 2024.
The largest trade he's ever made was exercising 97,000 units of Intellia Therapeutics Inc stock on 30 August 2021 worth over $1,358,970. On average, Laura trades about 8,119 units every 49 days since 2019. As of 8 January 2024 he still owns at least 43,927 units of Intellia Therapeutics Inc stock.
You can see the complete history of Laura Lorenzino stock trades at the bottom of the page.
Dr. Laura Sepp-Lorenzino serves as Executive Vice President, Chief Scientific Officer of the Company since May 2019. Prior to joining Intellia, Dr. Sepp-Lorenzino was vice president, head of nucleic acid therapies, research leadership and a member of the external innovation team at Vertex Pharmaceuticals, Inc. from September 2017 to May 2019. From April 2014 to September 2017, Dr. Sepp-Lorenzino was vice president, entrepreneur-in-residence and head of the hepatic infectious disease strategic therapeutic area at Alnylam Pharmaceuticals, Inc. Since October 2018, she has been a member of the scientific advisory board of Thermo Fisher Scientific. Dr. Sepp-Lorenzino earned a professional degree in biochemistry from the Universidad de Buenos Aires in Argentina and a Ph.D. in biochemistry from New York University.
As the Executive Vice President and Chief Scientific Officer of Intellia Therapeutics Inc, the total compensation of Laura Lorenzino at Intellia Therapeutics Inc is $1,762,490. There are no executives at Intellia Therapeutics Inc getting paid more.
Laura Lorenzino is 59, he's been the Executive Vice President and Chief Scientific Officer of Intellia Therapeutics Inc since 2019. There are 7 older and 12 younger executives at Intellia Therapeutics Inc. The oldest executive at Intellia Therapeutics Inc is Jesse Goodman, 68, who is the Independent Director.
Laura's mailing address filed with the SEC is C/O TAYSHA GENE THERAPIES, INC., 3000 PEGASUS PARK DRIVE, SUITE 1430, DALLAS, TX, 75247.
Over the last 9 years, insiders at Intellia Therapeutics Inc have traded over $210,567,884 worth of Intellia Therapeutics Inc stock and bought 1,285,277 units worth $23,117,886 . The most active insiders traders include Carl L Gordon, Jean Francois Formela, and Bros. Advisors Lpbaker Feli.... On average, Intellia Therapeutics Inc executives and independent directors trade stock every 27 days with the average trade being worth of $1,357,638. The most recent stock trade was executed by Eliana Clark on 1 July 2024, trading 405 units of NTLA stock currently worth $9,287.
intellia therapeutic’s core mission is to develop curative medicines, utilizing the promise of the crispr/cas9 gene editing technology. the development of crispr/cas9 gene editing technology opens a new frontier in biomedical research and clinical intervention. adapted from a natural cellular process, crispr/cas9 permits the editing of any gene in any organism with unprecedented simplicity and flexibility. the incredible potential of this technology for treating human genetic disease inspired a group of life science veterans to create intellia therapeutics. intellia was founded in 2014 by caribou biosciences and atlas venture, along with a consortium of scientists who have helped define the space. intellia therapeutics holds exclusive access to a broad intellectual property portfolio covering the application of crispr/cas9 technology for human therapeutic use. intellia has built an experienced team of individuals to meet the challenges of bringing crispr/cas9 therapeutics to the
Intellia Therapeutics Inc executives and other stock owners filed with the SEC include: